General Proximity

General Proximity is a biotechnology company that has developed OmniTAC, a proprietary, mechanism-agnostic discovery engine designed to identify effector proteins capable of modulating disease-driving, previously undruggable targets. The platform functions by identifying and facilitating specific proximity events between target and effector proteins, allowing for precise control of biological processes such as activation, refolding, or degradation. By leveraging this generalized approach, the company moves beyond traditional small-molecule limitations to discover therapeutic candidates for a broad range of biological pathways that were previously beyond the reach of medicine.

This technology is central to the company’s efforts to develop next-generation therapeutics for high-impact areas, including oncology, cardiometabolic disease, neurodegeneration, and longevity. The company’s innovative approach has garnered significant industry recognition and support, including non-dilutive grants from ARPA-H and the NIH’s National Cancer Institute, multiple pharmaceutical Golden Ticket awards, and a strategic multi-target collaboration with Daiichi Sankyo. By focusing on the effector-driven regulation of biology, General Proximity aims to address critical unmet medical needs and pioneer a new paradigm in induced-proximity drug discovery.